CONSORT diagram of patients in the trial. VTD, bortezomib, thalidomide,... | Download Scientific Diagram
![PDF] Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5d09b7e127f739fa3c3fa353bd310892f788ca9a/5-Table1-1.png "PDF] Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study | Semantic Scholar")
PDF] Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study | Semantic Scholar
Novel Three-Drug Combinations of Bortezomib, Thalidomide, Dexamethasone and Lenalidomide for Newly Diagnosed Multiple Myeloma (MM) | Research To Practice
D-VTd, daratumumab, bortezomib, thalidomide, dexamethasone; D-VRd,... | Download Scientific Diagram
The Korean Journal of Internal Medicine
British Journal of Haematology | Wiley Online Library
CASSIOPEIA part 2 | Int'l Myeloma Foundation
Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia - Biology
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial - The Lancet Haematology
Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation. - ppt download
![PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/96c7781d6fa4259ed9eba04dca6683938899d098/3-Table2-1.png "PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar")
PDF] Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. | Semantic Scholar
Current Oncology | Free Full-Text | Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis | Leukemia
Treatment indications of multiple myeloma VTD : Bortezomib -Thalidomide... | Download Scientific Diagram
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma: Hematology: Vol 12, No 3
VTd Vs Vd Vs VMP - Multiple Myeloma Clinical Trials
MM treatment tree outside clinical trials: front line. *Indicates data... | Download Scientific Diagram
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Darzalex ®▽ (daratumumab) approved for reimbursement in Ireland in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible - Hospital Professional News
Multiple Myeloma in: Journal of the National Comprehensive Cancer Network Volume 9 Issue 10 (2011)
Recommendations for MM front-line therapy. ASCT = autologous stem cell... | Download Scientific Diagram
